
Fulltext:
109372pub.pdf
Embargo:
until further notice
Size:
218.5Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2012Source
European Journal of Surgical Oncology, 38, 10, (2012), pp. 910-917ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Surgery
Pathology
Journal title
European Journal of Surgical Oncology
Volume
vol. 38
Issue
iss. 10
Page start
p. 910
Page end
p. 917
Subject
ONCOL 3: Translational research; ONCOL 3: Translational research NCEBP 2: Evaluation of complex medical interventions; ONCOL 4: Quality of CareAbstract
AIMS: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months and treatment options are usually restricted to palliative systemic therapy. The aim of this observational study was to evaluate the effectiveness and safety of resection of liver metastases from breast cancer and to identify prognostic factors for overall survival. METHODS: Patients were identified using the national registry of histo- and cytopathology in the Netherlands (PALGA). Included were all patients who underwent resection of liver metastases from breast cancer in 11 hospitals in The Netherlands of the last 20 years. Study data were retrospectively collected from patient files. RESULTS: A total of 32 female patients were identified. Intraoperative and postoperative complications occurred in 3 and 11 patients, respectively. There was no postoperative mortality. After a median follow up period of 26 months (range, 0-188), 5-year and median overall survival after partial liver resection was 37% and 55 months, respectively. The 5-year disease-free survival was 19% with a median time to recurrence of 11 months. Solitary metastases were the only independent significant prognostic factor at multivariate analysis. CONCLUSION: Resection of liver metastases from breast cancer is safe and might provide a survival benefit in a selected group of patients. Especially in patients with solitary liver metastasis, the option of surgery in the multimodality management of patients with disseminated breast cancer should be considered.
This item appears in the following Collection(s)
- Academic publications [227695]
- Electronic publications [108794]
- Faculty of Medical Sciences [87091]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.